OTHERS BCM ALLIANCE BERHAD ("BCM" OR "THE COMPANY") - MANUFACTURING AGREEMENT BETWEEN BC MEDICARE SDN. BHD., A WHOLLY-OWNED SUBSIDIARY OF BCM AND RLOOP LIMITED AND EURO-CHINA TECHNOLOGY ACHIEVEMENT TRANSFORMATION (TIANJIN) CO., LTD.
Reference is made to the Memorandum of Understanding entered between BC Medicare Sdn. Bhd. (“BC Medicare”), a wholly-owned subsidiary of BCM and rLoop Limited (“rLoop”) (individually referred to as “Party” and collectively referred to as “Parties”) on 26 July 2021, the Board of Directors of BCM (“Board”) wishes to announce that BC Medicare had on 23 December 2021 entered into a Manufacturing Agreement (“the Agreement”) with rLoop and Euro-China Technology Achievement Transformation (Tianjin) Co. Ltd (“EC”) to provide manufacturing services for the virus attenuation devices using photon mediated electrons and emitters under rLoop’s own brand name of “rGuard – rLoop Virus Attenuation Device” (“Product”).
BC Medicare had on 23 December 2021 entered into a Manufacturing Agreement (“the Agreement”) with rLoop and Euro-China Technology Achievement Transformation (Tianjin) Co. Ltd. (“EC”) to provide manufacturing services for the virus attenuation devices using photon mediated electrons and emitters under rLoop’s own brand name of “rGuard – rLoop Virus Attenuation Device”
INFORMATION ON BC MEDICARE, RLOOP AND EC
2.1 BC Medicare BC Medicare is a private limited company incorporated in Malaysia with its registered address at Third Floor, No. 77, 79 & 81, Jalan SS21/60, Damansara Utama, 47400 Petaling Jaya, Selangor Darul Ehsan. It is principally engaged in the business of designing, developing, manufacturing, testing, configuring, assembling, packaging and shipping electronic assemblies and systems.
2.2 rLoop Limited rLoop is a limited company incorporated in Hong Kong with its registered address at Suite 4703, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong. It has the licensed right for designing, manufacturing (including contract manufacturing), developing, distributing, marketing and selling the Product in various countries.
2.3 EC EC is a company incorporated in the People’s Republic of China with its registered office at Suite 6-402-7, 1-1, Harbour Venture Park, Lingang Economic Zone, Binhai New District, Tianjin City, the People’s Republic of China. It has agreed to purchase the agreed quantity of the Product from rLoop at the agreed price.
3.1 Transaction The details of the transaction are as below:-
(a) rLoop has engaged BC Medicare to manufacture, test, configure, assemble, pack and/or ship the Product.
(b) EC agrees to purchase 100,000 units of the Product from rLoop at a price of US$2,000 per unit with a total consideration of US$200 million, in which such price will include, inter alia, royalties, installation and debugging, operation and technology information training, data monitoring and maintenance services.
(c) The Product will be manufactured by BC Medicare in Malaysia under a separate Original Equipment Manufacturer (OEM) manufacturing agreement between BC Medicare and rLoop.
(d) BC Medicare will be responsible for providing training to EC on the functions and operations of the Product.
3.2 Purchase Order
The total quantity of the Product under the Agreement is 100,000 units. EC will place individual Purchase Order(s) to rLoop no less than 30 days before the scheduled delivery for each Purchase Order.
3.3 Price
US$2,000 per unit of the Product.
3.4 Payment Term
10% of the purchase sum for each Purchase Order shall be paid by EC in cash term within seven (7) days upon rLoop’s confirmation of receipt of the Purchase Order, and the remaining 90% shall be paid prior to shipment in form of standby letter of credit or any other banking instrument to be agreed by rLoop.
If BCMall price appreciated, which public listed company being a substantial shareholder with 7.88% will also reap the benefits from its BCMall investment
MANUFACTURING AGREEMENT BETWEEN BC MEDICARE SDN. BHD., A WHOLLY-OWNED SUBSIDIARY OF BCM AND RLOOP LIMITED AND EURO-CHINA TECHNOLOGY ACHIEVEMENT TRANSFORMATION (TIANJIN) CO., LTD.
SALIENT TERMS OF THE AGREEMENT
3.1 Transaction
The details of the transaction are as below:- (a) rLoop has engaged BC Medicare to manufacture, test, configure, assemble, pack and/or ship the Product.
(b) EC agrees to purchase 100,000 units of the Product from rLoop at a price of US$2,000 per unit with a total consideration of US$200 million, in which such price will include, inter alia, royalties, installation and debugging, operation and technology information training, data monitoring and maintenance services.
(c) The Product will be manufactured by BC Medicare in Malaysia under a separate Original Equipment Manufacturer (OEM) manufacturing agreement between BC Medicare and rLoop.
(d) BC Medicare will be responsible for providing training to EC on the functions and operations of the Product.
Purchase Order
The total quantity of the Product under the Agreement is 100,000 units. EC will place individual Purchase Order(s) to rLoop no less than 30 days before the scheduled delivery for each Purchase Order.
BCM, Hong Kong’s rLoop get RM845m order for Covid attenuation devices
PETALING JAYA: BCM Alliance Bhd via its wholly owned subsidiary BC Medicare Sdn Bhd and Hong Kong’s rLoop Limited have received a letter of offer from China’s Euro-China Technology Achievement Transformation (Tianjin) Co Ltd (EC Tech) to purchase 100,000 units of virus attenuation devices with a total sale of US$200 million (RM845 million).
This virus attenuation or reduction devices use photon mediated electrons and emitters under rLoop’s brand name “rGuard” in the global market except for India. The product can disable the coronavirus in enclosed spaces with up to 99.9% efficacy – enabling schools, colleges, homes and businesses like hospitals, hotels, offices, restaurants, auditoriums, transportation, retail and airports to get back to normal and serve people in a safe environment.
At US$2,000 per unit, the price will include royalties, installation & debugging, operations & technology information training, data monitoring and maintenance services.
BC Medicare is in the business of designing, developing, manufacturing, testing, configuring, assembling, packaging and shipping electronic assemblies and systems, whereas rLoop has the intellectual property rights and licensing right for designing, manufacturing (including contract manufacturing), developing, distributing, marketing and selling of these products.
On the same day, rLoop has engaged BCM Alliance via a memorandum of understanding (MoU) to manufacture, test, configure, assemble, pack and/or ship the virus attenuation or reduction devices as well as provision of manufacturing services for the product. A separate OEM manufacturing agreement between rLoop and BCM is underway. BCM will also be responsible for providing training to EC Tech on the functions and operations of the goods.
BCM Alliance executive director Hoo Swee Guan said the rGuard can be installed in all indoor areas and it has huge market potential.
“BCM is also authorised to market the products to global markets, except India. Fortunately, we receives a big order of US$200 million before we even started, and the future sales volume will bring considerable turnover to our group,” Hoo added.
All three parties would be negotiating towards a definitive agreement to formalise this significant order. The tri-partite definitive agreement will contain detailed terms in the following aspects as well as such other terms and conditions that are standard for transactions of this nature and acceptable to the signing parties – such as specifications and packaging, quantity (number of shipments and quantity of each shipment), price terms, delivery schedule, destination, payment terms, quality and inspection (return policy), installation & debugging, training, warranty and maintenance.
JuliusCeasar Old news! See the date June 2021! ------------ Its an updated news.
The MANUFACTURING AGREEMENT BETWEEN BC MEDICARE SDN. BHD., A WHOLLY-OWNED SUBSIDIARY OF BCM AND RLOOP LIMITED AND EURO-CHINA TECHNOLOGY ACHIEVEMENT TRANSFORMATION (TIANJIN) CO., LTD. has been signed in...
Off course would not have impact on financial performances for 2021.. Already end of the year..
Now try to see what would happen for the next QR if the product get delivered.. 100,000 units & USD$2000 per unit..
I think not a problem if not LIMIT UP.. more time for collect ... ....
3 7. APPROVAL REQUIRED The Agreement is not subject to the approval of the shareholders of BCM and/or any regulatory authorities. 8. INTERESTS OF DIRECTORS, MAJOR SHAREHOLDERS AND/ OR PERSONS CONNECTED TO THEM None of the Directors, major shareholders of the Company and/or persons connected to them have any interest, whether direct or indirect, in the Agreement. 9. STATEMENT OF THE DIRECTORS The Board, having taken into consideration all aspects of the Agreement, is of the opinion that the Agreement is in the best interest of the Company. 10. DOCUMENTS AVAILABLE FOR INSPECTION The Agreement is available for inspection at the registered office of the Company at Third Floor, No. 77, 79 & 81, Jalan SS21/60, Damansara Utama, 47400 Petaling Jaya, Selangor Darul Ehsan, during normal business hours from Monday to Friday (except public holidays) for a period of three (3) months from the date of this announcement.
No need to quarrel yerrr! Let's see what happen by end of this Friday. Another 3 trading days to go. The truth will reveal! GORENGGGG UP OR MAJOR SELL-OFF GORENGGGG DOWN.
When syndicate ppl goreng the pennytstocks, the non-syndicates get itchy hands and join in the goreng, who don't want to make quick money. The bluechips fellows too goreng their bluechips shares.
Which public listed company is a substantial shareholder of BCMall? If BCMall price jump up substantially that cash rich public listed company will reap huge profit. Buy
I am surprised BCMall is allowed to issue 469M BCMall shares under ESOS scheme without having to call for an EGM or get SC approval. Something is very wrong. Instead of protecting the interest of minority shareholders SC is allowing excessive dilution of capital at the expense of small shareholders. Assuming BCMall have 100 employees, in theory each employee will be offered 4.69M BCMall shares valued at RM140,700. It makes me wonder how many employee have available cash of RM140,700 to buy 4.69M BCMall shares
Reap88 I am surprised BCMall is allowed to issue 469M BCMall shares under ESOS scheme without having to call for an EGM or get SC approval. Something is very wrong. Instead of protecting the interest of minority shareholders SC is allowing excessive dilution of capital at the expense of small shareholders. Assuming BCMall have 100 employees, in theory each employee will be offered 4.69M BCMall shares valued at RM140,700. It makes me wonder how many employee have available cash of RM140,700 to buy 4.69M BCMall shares 13/01/2022 1:44 PM
why would BCMall issued shares under ESOS, anybody?
pineapple123 ......why would BCMall issued shares under ESOS, anybody?
------------- NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) : ESOS BCM ALLIANCE BERHAD ("BCM" OR THE "COMPANY") PROPOSED ESTABLISHMENT OF AN EMPLOYEES' SHARE OPTIONS SCHEME INVOLVING UP TO 30% OF THE TOTAL NUMBER OF ISSUED SHARES OF THE COMPANY (EXCLUDING TREASURY SHARES, IF ANY) FOR ELIGIBLE DIRECTORS AND EMPLOYEES OF THE COMPANY AND ITS SUBSIDIARIES ("ESOS")
Reference is made to the earlier announcements in relation to the ESOS dated 5 February 2021 and 15 February 2021.
On behalf of the Board, Mercury Securities wishes to announce that the effective date for the implementation of the ESOS is 25 March 2021, being the date on which the Company is in full compliance with all relevant requirements including Rule 6.44(1) of the Listing Requirements.
BCMall will not be clasified as PN17 listed issuer counter. Its listed on ACE market. He He
Do you think based on these items in its balance sheet, the company is closing its businesses and be classified as GN3 listed issuer counter especially in near future ?
Do you know, on what condition a specific company will be classified as PN17 or GN3 listed company ?
THE LATEST EQUITY OF BCMALL
EQUITY (RM)
Share capital 153,570,000 Merger reserves(16,049,000) Revaluation reserves 5,109,000 Warrant reserve (29,004,000) Other reserve 29,004,000
After this, there will be a specific announcement (Additional Listing Announcement / Subdivision of Shares) when the specific batch of shares from the exercise of ESOS are going to be listed.
It will stated the quantity of shares are going to be listing and the date of the listing...
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
MZM2511
4,550 posts
Posted by MZM2511 > 2021-12-24 17:53 | Report Abuse
OTHERS BCM ALLIANCE BERHAD ("BCM" OR "THE COMPANY") - MANUFACTURING AGREEMENT BETWEEN BC MEDICARE SDN. BHD., A WHOLLY-OWNED SUBSIDIARY OF BCM AND RLOOP LIMITED AND EURO-CHINA TECHNOLOGY ACHIEVEMENT TRANSFORMATION (TIANJIN) CO., LTD.
Reference is made to the Memorandum of Understanding entered between BC Medicare Sdn. Bhd. (“BC Medicare”), a wholly-owned subsidiary of BCM and rLoop Limited (“rLoop”) (individually referred to as “Party” and collectively referred to as “Parties”) on 26 July 2021, the Board of Directors of BCM (“Board”) wishes to announce that BC Medicare had on 23 December 2021 entered into a Manufacturing Agreement (“the Agreement”) with rLoop and Euro-China Technology Achievement Transformation (Tianjin) Co. Ltd (“EC”) to provide manufacturing services for the virus attenuation devices using photon mediated electrons and emitters under rLoop’s own brand name of “rGuard – rLoop Virus Attenuation Device” (“Product”).
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3221378